All In Biotech

Drug Trial Radar · NCT02996110

A Study to Test Combination Treatments in People With Advanced Renal Cell Carcinoma

A Phase 2, Real-time Assessment of Combination Therapies in Immuno-Oncology Study in Participants With Advanced Renal Cell Carcinoma (FRACTION-RCC)

Last checked: Nov 19, 2026Latest source record: Dec 19, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 182 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

182

Actual

Start

Feb 2, 2017

Primary completion

Nov 23, 2021

Study completion Nov 23, 2021

Sponsor

Lead sponsor
Bristol-Myers SquibbBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Dec 19, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to test the effectiveness and safety of various nivolumab combinations compared to nivolumab and ipilimumab in participants with advanced kidney cancer

Conditions

  • Advanced Cancer

Interventions

  • NivolumabBiological

    Specified Dose on Specified Days

  • IpilimumabBiological

    Specified Dose on Specified Days

  • RelatlimabBiological

    Specified Dose on Specified Days

  • BMS-986205Drug

    Specified Dose on Specified Days

  • BMS-813160Drug

    Specified Dose on Specified Days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate (ORR) Per InvestigatorTime frame: From first dose of study treatment until progression or subsequent anticancer therapy, whichever occurs first (assessed up to approximately 247 weeks)
  2. Median Duration of Response (DOR) Per InvestigatorTime frame: From first dose to the date of first documented disease progression or death due to any cause (assessed from an average of 22 weeks up to approximately 247 weeks)
  3. Progression Free Survival Rate (PFSR) at 24 Weeks.Time frame: 24 weeks after first treatment dose.

Locations

32 sites in 6 countries. Site status is shown where the registry gives one.

  • Local Institution - 0037

    New Haven, Connecticut

  • Local Institution

    Tampa, Florida

  • Local Institution - 0031

    Augusta, Georgia

  • Local Institution - 0006

    Chicago, Illinois

  • Local Institution - 0007

    Baltimore, Maryland

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Local Institution - 0011

    Detroit, Michigan

  • Local Institution - 0008

    St Louis, Missouri

  • Roswell Park Cancer Institute

    Buffalo, New York

  • Local Institution - 0005

    New York, New York

  • Local Institution - 0043

    Charlotte, North Carolina

  • Local Institution - 0014

    Columbus, Ohio

  • Oregon Health & Science University

    Portland, Oregon

  • Local Institution - 0002

    Allentown, Pennsylvania

  • Hollings Cancer Center

    Charleston, South Carolina

  • Local Institution - 0025

    Nashville, Tennessee

  • Ut Southwestern Medical Center

    Dallas, Texas

  • Local Institution - 0024

    Charlottesville, Virginia

  • University of Washington - Seattle Cancer Care Alliance

    Seattle, Washington

  • Local Institution - 0032

    Westmead, New South Wales, Australia

  • Monash Medical Centre Clayton

    Bentleigh, Victoria, Australia

  • Local Institution - 0044

    Linz, Upper Austria, Austria

  • Local Institution - 0038

    Hamilton, Ontario, Canada

  • Local Institution - 0029

    Oshawa, Ontario, Canada

  • Local Institution - 0035

    Toronto, Ontario, Canada

  • Local Institution - 0034

    Montreal, Quebec, Canada

  • Local Institution - 0030

    Québec, Quebec, Canada

  • Local Institution

    Haifa, Israel

  • Local Institution

    Ramat Gan, Israel

  • Local Institution - 0010

    Milan, Italy

  • Local Institution - 0012

    Naples, Italy

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.